These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 37312864)

  • 1. Novel C-Linked Isoquinoline Amides as LRRK2 Inhibitors for Treating Parkinson's Disease.
    Sabnis RW; Sabnis AR
    ACS Med Chem Lett; 2023 Jun; 14(6):698-699. PubMed ID: 37312864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel N-Linked Isoquinoline Amides as LRRK2 Inhibitors for Treating Parkinson's Disease.
    Sabnis RW
    ACS Med Chem Lett; 2022 Jul; 13(7):1008-1009. PubMed ID: 35928851
    [No Abstract]   [Full Text] [Related]  

  • 3. New Pyrrolopyrimidines as LRRK2 Inhibitors for Treating Parkinson's Disease.
    De SK
    Curr Med Chem; 2023 Aug; ():. PubMed ID: 37605404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pyridazine Derivatives as NLRP3 Inhibitors for Treating Asthma, COPD, Parkinson's Disease, and Alzheimer's Disease.
    Sabnis RW
    ACS Med Chem Lett; 2023 Aug; 14(8):1047-1048. PubMed ID: 37583813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease.
    Nichols RJ; Dzamko N; Hutti JE; Cantley LC; Deak M; Moran J; Bamborough P; Reith AD; Alessi DR
    Biochem J; 2009 Oct; 424(1):47-60. PubMed ID: 19740074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitor treatment of peripheral mononuclear cells from Parkinson's disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker.
    Perera G; Ranola M; Rowe DB; Halliday GM; Dzamko N
    Sci Rep; 2016 Aug; 6():31391. PubMed ID: 27503089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lysosomal Pathogenesis of Parkinson's Disease: Insights From LRRK2 and GBA1 Rodent Models.
    Volta M
    Neurotherapeutics; 2023 Jan; 20(1):127-139. PubMed ID: 36085537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid pathway dysfunction is prevalent in patients with Parkinson's disease.
    Galper J; Dean NJ; Pickford R; Lewis SJG; Halliday GM; Kim WS; Dzamko N
    Brain; 2022 Oct; 145(10):3472-3487. PubMed ID: 35551349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rab12 is a regulator of LRRK2 and its activation by damaged lysosomes.
    Wang X; Bondar VV; Davis OB; Maloney MT; Agam M; Chin MY; Cheuk-Nga Ho A; Ghosh R; Leto DE; Joy D; Calvert MEK; Lewcock JW; Di Paolo G; Thorne RG; Sweeney ZK; Henry AG
    Elife; 2023 Oct; 12():. PubMed ID: 37874617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LRRK2 haplotype-sharing analysis in Parkinson's disease reveals a novel p.S1761R mutation.
    Lorenzo-Betancor O; Samaranch L; Ezquerra M; Tolosa E; Lorenzo E; Irigoyen J; Gaig C; Pastor MA; Soto-Ortolaza AI; Ross OA; Rodríguez-Oroz MC; Valldeoriola F; Martí MJ; Luquin MR; Perez-Tur J; Burguera JA; Obeso JA; Pastor P
    Mov Disord; 2012 Jan; 27(1):146-51. PubMed ID: 22038903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small-Molecule Inhibitors of LRRK2.
    Hatcher JM; Choi HG; Alessi DR; Gray NS
    Adv Neurobiol; 2017; 14():241-264. PubMed ID: 28353288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitors of leucine-rich repeat kinase 2 (LRRK2): progress and promise for the treatment of Parkinson's disease.
    Gilligan PJ
    Curr Top Med Chem; 2015; 15(10):927-38. PubMed ID: 25832719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LRRK2 and Proteostasis in Parkinson's Disease.
    Pérez-Carrión MD; Posadas I; Solera J; Ceña V
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein synthesis is suppressed in sporadic and familial Parkinson's disease by LRRK2.
    Deshpande P; Flinkman D; Hong Y; Goltseva E; Siino V; Sun L; Peltonen S; Elo LL; Kaasinen V; James P; Coffey ET
    FASEB J; 2020 Nov; 34(11):14217-14233. PubMed ID: 32926469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LRRK2 kinase inhibitors reduce alpha-synuclein in human neuronal cell lines with the G2019S mutation.
    Zhao Y; Keshiya S; Perera G; Schramko L; Halliday GM; Dzamko N
    Neurobiol Dis; 2020 Oct; 144():105049. PubMed ID: 32800998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent Developments in LRRK2-Targeted Therapy for Parkinson's Disease.
    Zhao Y; Dzamko N
    Drugs; 2019 Jul; 79(10):1037-1051. PubMed ID: 31161537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic analysis of Mendelian mutations in a large UK population-based Parkinson's disease study.
    Tan MMX; Malek N; Lawton MA; Hubbard L; Pittman AM; Joseph T; Hehir J; Swallow DMA; Grosset KA; Marrinan SL; Bajaj N; Barker RA; Burn DJ; Bresner C; Foltynie T; Hardy J; Wood N; Ben-Shlomo Y; Grosset DG; Williams NM; Morris HR
    Brain; 2019 Sep; 142(9):2828-2844. PubMed ID: 31324919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models.
    Kramer T; Lo Monte F; Göring S; Okala Amombo GM; Schmidt B
    ACS Chem Neurosci; 2012 Mar; 3(3):151-60. PubMed ID: 22860184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET study.
    Liu SY; Wile DJ; Fu JF; Valerio J; Shahinfard E; McCormick S; Mabrouk R; Vafai N; McKenzie J; Neilson N; Perez-Soriano A; Arena JE; Cherkasova M; Chan P; Zhang J; Zabetian CP; Aasly JO; Wszolek ZK; McKeown MJ; Adam MJ; Ruth TJ; Schulzer M; Sossi V; Stoessl AJ
    Lancet Neurol; 2018 Apr; 17(4):309-316. PubMed ID: 29456161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LRRK2 levels and phosphorylation in Parkinson's disease brain and cases with restricted Lewy bodies.
    Dzamko N; Gysbers AM; Bandopadhyay R; Bolliger MF; Uchino A; Zhao Y; Takao M; Wauters S; van de Berg WD; Takahashi-Fujigasaki J; Nichols RJ; Holton JL; Murayama S; Halliday GM
    Mov Disord; 2017 Mar; 32(3):423-432. PubMed ID: 27911006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.